正在进行的关于使用牛奶配方和坏死性小肠结肠炎的诉讼:产品责任问题和知情同意的拟议要求。

IF 2.1 3区 医学 Q2 OBSTETRICS & GYNECOLOGY
Breastfeeding Medicine Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI:10.1089/bfm.2024.0321
T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman
{"title":"正在进行的关于使用牛奶配方和坏死性小肠结肠炎的诉讼:产品责任问题和知情同意的拟议要求。","authors":"T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman","doi":"10.1089/bfm.2024.0321","DOIUrl":null,"url":null,"abstract":"<p><p>Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed \"premature special care formulas.\" The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant \"approval\" status, as the FDA classifies these \"special care formulas\" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further \"special care formula\" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a \"special care formula.\" In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.</p>","PeriodicalId":9142,"journal":{"name":"Breastfeeding Medicine","volume":" ","pages":"1-4"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ongoing Litigation Regarding the Use of Cow's Milk Formulas and Necrotizing Enterocolitis: Issues of Product Liability and Proposed Requirement for Informed Consent.\",\"authors\":\"T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman\",\"doi\":\"10.1089/bfm.2024.0321\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed \\\"premature special care formulas.\\\" The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant \\\"approval\\\" status, as the FDA classifies these \\\"special care formulas\\\" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further \\\"special care formula\\\" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a \\\"special care formula.\\\" In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.</p>\",\"PeriodicalId\":9142,\"journal\":{\"name\":\"Breastfeeding Medicine\",\"volume\":\" \",\"pages\":\"1-4\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breastfeeding Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/bfm.2024.0321\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breastfeeding Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/bfm.2024.0321","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

最近针对美国两家主要配方奶粉制造商的产品责任诉讼,在吉尔诉雅培实验室和沃森诉美赞臣案中,美国两个州的陪审团认定,这两家制造商因未能警告父母和医疗专业人员其配方奶粉会增加坏死性小肠结肠炎(NEC)的风险而制造了产品责任。他们声称他们的产品安全有效。在这两起案件中,州法院的陪审团都为那些因喂食“过早的特殊护理配方奶粉”而死亡的婴儿的父母做出了巨额的惩罚性损害赔偿、经济和情感伤害赔偿。该公司的辩护律师主张有学问的中介学说,即是新生儿医生订购和/或给早产儿使用这些产品,从而导致NEC,但没有成功。美国食品和药物管理局(FDA)对配方生产过程有监管权力,但不授予“批准”地位,因为FDA将这些“特殊护理配方”归类为豁免,因为它们是营养制剂。虽然这两起案件都在上诉中,但这些法律行动的影响可能会阻碍“特殊护理配方”的进一步发展,并可能在婴儿服用“特殊护理配方”后出现NEC时,造成医生渎职指控的风险。根据美国儿科学会的建议,获得配方奶粉使用的知情同意可能会减轻新生儿医生和其他医疗服务提供者的一些法律风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ongoing Litigation Regarding the Use of Cow's Milk Formulas and Necrotizing Enterocolitis: Issues of Product Liability and Proposed Requirement for Informed Consent.

Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed "premature special care formulas." The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant "approval" status, as the FDA classifies these "special care formulas" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further "special care formula" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a "special care formula." In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breastfeeding Medicine
Breastfeeding Medicine OBSTETRICS & GYNECOLOGY-PEDIATRICS
CiteScore
4.20
自引率
11.10%
发文量
130
审稿时长
6-12 weeks
期刊介绍: Breastfeeding Medicine provides unparalleled peer-reviewed research, protocols, and clinical applications to ensure optimal care for mother and infant. The Journal answers the growing demand for evidence-based research and explores the immediate and long-term outcomes of breastfeeding, including its epidemiologic, physiologic, and psychological benefits. It is the exclusive source of the Academy of Breastfeeding Medicine protocols. Breastfeeding Medicine coverage includes: Breastfeeding recommendations and protocols Health consequences of artificial feeding Physiology of lactation and biochemistry of breast milk Optimal nutrition for the breastfeeding mother Breastfeeding indications and contraindications Managing breastfeeding discomfort, pain, and other complications Breastfeeding the premature or sick infant Breastfeeding in the chronically ill mother Management of the breastfeeding mother on medication Infectious disease transmission through breast milk and breastfeeding The collection and storage of human milk and human milk banking Measuring the impact of being a “baby-friendly” hospital Cultural competence and cultural sensitivity International public health issues including social and economic issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信